Viking Therapeutics VKTX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$158.33M-247% | -$157.66M-345% | -$90.79M-264% | -$65.56M-195% | -$45.63M-66.8% | ||
| $10.34M-8.9% | $8.59M+51.5% | $7.34M-18.3% | $13.55M+91.3% | $11.35M+42.2% | ||
| $13.93M+760% | $48.84M+411% | -$1.08M+90.0% | -$2.21M-138% | -$2.11M+7.7% | ||
| $15.86M+376% | $2.07M— | —— | $14.64M— | -$5.74M-136% | ||
| -$4.63M-148% | —— | $4.83M+77.2% | $5.09M— | $9.55M+647% | ||
| $85K-23.4% | $94K-14.5% | $114K+31.0% | $112K+49.3% | $111K+50.0% | ||
| -$139K-7.8% | -$116K+9.4% | -$130K-35.4% | -$130K-44.4% | -$129K-46.6% | ||
| -$113.98M-118% | -$85.29M-174% | -$94M-328% | -$47.06M-65.1% | -$52.33M-753% | ||
| $72.44M-68.9% | $40.49M-70.4% | $21.45M-85.7% | $123.48M-46.3% | $232.61M-61.0% | ||
| $126.63M-57.2% | $116.11M-19.1% | $181.48M+3.2% | $165.98M+60.0% | $295.86M+116% | ||
| $54.19M-14.3% | $75.61M— | $160.03M— | $42.51M+134% | $63.25M+114% | ||
| $450K+28.9% | —— | $480K-81.0% | $507K-82.7% | $349K-92.0% | ||
| —— | $0— | $0— | —— | —— | ||
| $12.08M+3,360% | $75.1M+7,410% | $480K-81.0% | $507K-82.5% | $349K-99.9% | ||
| $16K+1,500% | —— | -$6K+79.3% | -$12K— | $1K+102% | ||
| -$47.71M-524% | $65.43M+377% | $66.5M— | $0+100% | $11.26M-92.0% | ||
| $1.29M-58.7% | $1.73M-57.1% | $2.03M-59.2% | $2.39M-56.0% | $3.13M+11.1% | ||
| $0-100% | $0-100% | $8K-66.7% | $24K+33.3% | $24K-14.3% | ||
| -$139K-7.8% | -$116K+9.4% | -$130K-35.4% | -$130K-44.4% | -$129K-46.6% | ||
| -$4.63M-148% | —— | $4.83M+77.2% | $5.09M— | $9.55M+647% | ||
| $85K-23.4% | $94K-14.5% | $114K+31.0% | $112K+49.3% | $111K+50.0% | ||
| $1K-90.0% | —— | $8K-11.1% | $8K-11.1% | $10K+11.1% | ||
| $126.63M-57.2% | $116.11M-19.1% | $181.48M+3.2% | $165.98M+60.0% | $295.86M+116% | ||
| $11.63M— | $73.95M— | $0— | $0— | $0-100% | ||
| $450K+28.9% | —— | $480K-81.0% | $507K-82.7% | $349K-92.0% | ||
| $16K+1,500% | —— | -$6K+79.3% | -$12K— | $1K+102% | ||
| -$139K-7.8% | -$116K+9.4% | -$130K-35.4% | -$130K-44.4% | -$129K-46.6% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $50K0.0% | —— | —— | —— | $50K-27.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.